Ipsen will not go it alone with taspoglutide
This article was originally published in Scrip
Executive Summary
Ipsen says it will not pursue any further clinical development of the GLP-1 analogue taspoglutide on its own, following Roche's decision to abandon the increasingly problematic diabetes drug candidate and return it to its French development partner (scripintelligence.com, 2 February 2011).